Catalog No.
Product Name
Application
Product Information
Product Citation
- YIL 781 is a ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM)
- Lin D, .et al. , Endocrinology. , 2014, 155(7):2355-62 PMID: 24735326
- Anamorelin is currently under development for the management of non-small lung cancer associated cachexia/anorexia.
- Makito Miyake, .et al. , Cancers (Basel), 2020, Jul 17;12(7):E1942 PMID: 32709007
-
GHSR agonist
Anamorelin (ONO-7643, RC-1291, ST-1291) is an orally active, high-affinity, selective agonist of the ghrelin receptor with an EC50 value of 0.74 nM in the HEK293/GRLN FLIPR assay. Anamorelin is currently under development for the management of non-small lung cancer associated cachexia/anorexia.
- Josua Jordi, .et al. , Sci Adv, 2018, Oct; 4(10): eaav1966 PMID: 30402545
- Capromorelin functions as a growth hormone secretagogue and ghrelin mimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood.
-
GHSR stimulator
Anamorelin fumarate is a synthetic orally active ghrelin receptor agonist which is under development for the management of non-small lung cancer associated cachexia/anorexia. -
GHSR agonist
Capromorelin Tartrate is an orally active, potent growth hormone secretagogue receptor (GHSR) agonist, with Ki of 7 nM for hGHS-R1a. -
ghrelin receptor inverse agonist
PF-5190457 is a potent and selective ghrelin receptor inverse agonist with a pKi of 8.36. -
GHSR ligand
des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.